CRISPR/Cas9-based gene therapy (CRISPR Therapeutics/Anagenesis Biotechnologies)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCRISPR/Cas9-based gene therapy (CRISPR Therapeutics/Anagenesis Biotechnologies)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionDystrophin gene transference
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrispr Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCrispr Therapeutics Ag
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A